Mei Ri Jing Ji Xin Wen·2025-11-04 08:42Company Summary - Rongchang Biopharmaceutical (SH 688331) held its 30th meeting of the second board on November 4, 2025, to discuss the proposal regarding the first vesting period of the 2022 A-share restricted stock incentive plan [1] - For the year 2024, the company's revenue composition is 99.61% from the pharmaceutical manufacturing industry and 0.39% from other businesses [1] - As of the report date, Rongchang Biopharmaceutical has a market capitalization of 54.5 billion yuan [1] Industry Summary - A significant increase in overseas orders by 246% has been reported, covering over 50 countries and regions [1] - Entrepreneurs have raised concerns about some companies selling products at a loss, warning of potential vicious competition extending to overseas markets [1]